151 related articles for article (PubMed ID: 16469011)
1. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer.
Murthy V; Norman AR; Shahidi M; Parker CC; Horwich A; Huddart RA; Bange A; Dearnaley DP
BJU Int; 2006 Mar; 97(3):476-9. PubMed ID: 16469011
[TBL] [Abstract][Full Text] [Related]
2. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.
Shahidi M; Norman AR; Gadd J; Huddart RA; Horwich A; Dearnaley DP
Clin Oncol (R Coll Radiol); 2001; 13(4):291-5. PubMed ID: 11554629
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.
Murthy V; Norman AR; Barbachano Y; Parker CC; Dearnaley DP
BJU Int; 2007 Jun; 99(6):1380-2. PubMed ID: 17537213
[TBL] [Abstract][Full Text] [Related]
4. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
5. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
7. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
[TBL] [Abstract][Full Text] [Related]
8. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
10. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists.
Wilke DR; Parker C; Andonowski A; Tsuji D; Catton C; Gospodarowicz M; Warde P
BJU Int; 2006 May; 97(5):963-8. PubMed ID: 16542340
[TBL] [Abstract][Full Text] [Related]
11. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
[TBL] [Abstract][Full Text] [Related]
12. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
14. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
16. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer.
Bertaglia V; Tucci M; Fiori C; Aroasio E; Poggio M; Buttigliero C; Grande S; Saini A; Porpiglia F; Berruti A
Clin Genitourin Cancer; 2013 Sep; 11(3):325-330.e1. PubMed ID: 23531429
[TBL] [Abstract][Full Text] [Related]
17. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
[TBL] [Abstract][Full Text] [Related]
18. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
Pickles T; Agranovich A; Berthelet E; Duncan GG; Keyes M; Kwan W; McKenzie MR; Morris WJ;
Cancer; 2002 Jan; 94(2):362-7. PubMed ID: 11900222
[TBL] [Abstract][Full Text] [Related]
19. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
Oefelein M
J Urol; 2003 Jan; 169(1):251-5. PubMed ID: 12478147
[TBL] [Abstract][Full Text] [Related]
20. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
